American multinational biotechnology company
Biogen Stock Rises After Earnings and on Jump in Alzheimer’s Drug Sales: Biogen reported first-quarter adjusted earnings of $3.67 a share on revenue of $2 ...
barrons.com/articles/biogen-earnings-stock-price-fda73be6
Paid articlePaid
Alzheimer's drug adoption in US slowed by doctors' skepticism: Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's ...
reut.rs/3Wbq0wc
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript: Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ETCompany ...
seekingalpha.com/article/4685686-biogen-inc-biib-q1-2024-earnings-call-transcript
Quick Glance: Success in Q1 2024 for Biogen
- Strong performance in the first quarter of 2024 showcased Biogen's impressive earnings per share growth.
- A shift towards supporting patients with Alzheimer's, Friedreich's Ataxia, and postpartum depression is a key focus.
- LEQEMBI and SKYCLARYS are showing promising results, prompting an expansion of the sales team to enhance market presence.
- The company remains committed to optimizing its R&D pipeline, emphasizing the development of new treatments for rare diseases and immunological conditions.
Biogen Surges After Two Notable Drugs Wallop Sales Forecasts: Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday ...
investors.com/news/technology/biogen-stock-biogen-earnings-leqembi-skyclarys-q1-2023/
Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US rollout
ft.com/content/1e02c10c-f7c4-48e9-a6a4-774531b56350
Drug sales keep beating Wall Street's expectations and boosting some pharma stocks
qz.com/pharma-sales-q1-1851435519
15 Stocks That Have Destroyed the Most Wealth Over the Past Decade: These stocks have eroded shareholder value in dollar terms.
morningstar.com/stocks/15-stocks-that-have-destroyed-most-wealth-over-past-decade
The Dow falls as Tesla rally can't sustain the market: Meta and IBM will release their quarterly reports after the closing bell
qz.com/dow-jones-tesla-meta-markets-1851433129
Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup
qz.com/ozempic-wegovy-weight-loss-drug-prices-moderna-biogen-1851436487
EU regulator delays decision on Eisai-Biogen Alzheimer's drug: The European Union's medicines regulator has delayed its decision on Eisai and partner Biogen's ...
reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-does-not-refer-eisai-biogen-alzheimers-drug-meeting-notes-2024-03-22/
Eli Lilly's new Alzheimer's drug just hit an unexpected snag with the FDA: The pharmaceutical company's stock dipped as the U.S. regulator announced plans to ...
qz.com/eli-lilly-alzheimers-drug-delay-fda-stock-1851321132
Paid articlePaidQuick Glance: F.D.A. Delays Approval of Alzheimer's Drug
- The F.D.A. has decided to delay action on the closely watched Alzheimer's drug, Donanemab, which was expected to be approved this month.
- Eli Lilly and Company will subject Donanemab to scrutiny by a panel of independent experts, the company said.
- The decision is likely to surprise many Alzheimer's experts, doctors, and patients who had expected the medication to be on the market soon.
- The F.D.A. did not provide a public statement on the move, which will delay a decision on approving Donanemab until at least later this year.
Biogen gets DOJ subpoena on business operations in foreign countries: Biogen has received a subpoena from the U.S. Department of Justice seeking information ...
reuters.com/business/healthcare-pharmaceuticals/biogen-receives-subpoena-doj-business-operations-foreign-countries-2024-02-14/
Biogen Promised a Return to Growth. Why the Stock Is Dropping.: Biogen’s new CEO, Christopher Viehbacher, said the company is well positioned to return to ...
barrons.com/articles/biogen-stock-earnings-0aff4a1f
Paid articlePaid
AI Impact Tour arrives in Boston on March 27: A focus on data integrity in generative AI
venturebeat.com/ai/ai-impact-tour-arrives-in-boston-on-march-27-a-focus-on-data-integrity-in-generative-ai/
Quick Glance: EU AI Act Approved by European Parliament
- The European Parliament overwhelmingly voted in favor of the AI Act, positioning the EU as a global leader in regulating AI software.
- The legislation establishes a risk-based framework for AI, applying rules and requirements based on the level of risk associated with the use case.
- Penalties for non-compliance under the Act can reach up to 7% of global annual turnover or €35M.
- The AI Act, shaped through extensive negotiations, is expected to be fully implemented by mid-2027.
We’re counting down the days until we join leaders from @MSCloud, @StateStreet, and @Biogen in Boston on March 27! Check out the full agenda and register for ...
bit.ly/49QIeqFShow
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript): Biogen Inc. (NASDAQ:NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19 ...
seekingalpha.com/article/4679198-biogen-inc-biib-stifel-2024-virtual-cns-days-transcript
Biogen expects to return to profit growth this year: Biogen (BIIB.O) forecast a return to annual profit growth following cost cuts and a pick up in sales of its ...
reuters.com/business/healthcare-pharmaceuticals/biogen-fourth-quarter-profit-misses-aduhelm-exit-costs-2024-02-13/
Quick Glance: Ex-FBI Informant Charged with Lying about Joe Biden and Son
- The U.S. special counsel leading a criminal probe into President Joe Biden's son, Hunter Biden, charged a former FBI informant for lying about their alleged involvement in business dealings with Ukrainian energy company Burisma Holdings.
- A federal grand jury indicted Alexander Smirnov, 43, for making false statements and creating a false record in relation to an FBI probe.
- The indictment states that Smirnov falsely recounted meetings where Burisma executives claimed to have hired Hunter Biden to solve problems through his father.
- Smirnov falsely claimed that Burisma executives paid $5 million to Joe Biden and Hunter Biden for his son to address issues through his father during a criminal investigation.
Ensuring Data Integrity for AI – The AI Impact Tour
impact.venturebeat.com/ai-impact-tour/ensuring-data-integrity-for-ai/
Biogen launch of Leqembi Alzheimer’s drug off to slow start: Only about 2,000 patients are taking the medicine nationwide, but Biogen’s chief executive ...
bostonglobe.com/2024/02/13/business/biogen-leqembi-alzheimers-eisai-christopher-a-viebacher/
Vivoryon: Alzheimer's study disappoints - Stock collapses: Vivoryon's Alzheimer's drug varoglutamstat misses all endpoints in phase 2b study.
deraktionaer.de/artikel/pharma-biotech/vivoryon-alzheimer-studie-enttaeuscht-aktie-bricht-ein-20351928.html
Nvidia and Cathie Wood invest in these relatively unknown AI stocks - Should you do it too?
boerse-online.de/nachrichten/aktien/nvidia-und-cathie-wood-investieren-in-diese-eher-unbekannte-ki-aktien-sollten-sie-es-auch-tun-20351191.html
Despite the tech rally: These are the losers in the Nasdaq 100 since the beginning of the year - Tesla, Intel & Co.
boerse-online.de/nachrichten/aktien/trotz-tech-rallye-das-sind-die-loser-im-nasdaq-100-seit-jahresanfang-tesla-intel-co-20351116.html
Limerick-based Kneat Solutions raises €13.7m in share offering: Eight of the world’s top pharma companies rely on Kneat’s technology, with customers that include ...
businesspost.ie/tech/limerick-based-kneat-solutions-raises-e13-7m-in-share-offering/
Paid articlePaid Biogen on Tuesday forecast flat 2024 product revenue as top-selling drugs face tough competition and sales of newer treatments take off slowly ... Show more
reut.rs/3SLHhc6
reut.rs/3SLHhc6
reut.rs/3SLHhc6
reut.rs/3SLHhc6
Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade): Biogen's significant investments in Alzheimer's treatments, especially Leqembi ...
seekingalpha.com/article/4670032-biogen-stock-q4-earnings-disappoint-amidst-strategic-challenges-downgrade-sell
Paid articlePaid Closing bell: Interest rate hopes evaporate, Dow Jones & Co fall - Boeing under pressure again - Disney and AI stocks hold up
deraktionaer.de/artikel/maerkte-forex-zinsen/schlussglocke-zinshoffnungen-verfliegen-dow-jones-co-fallen-boeing-wieder-unter-druck-disney-und-ki-aktien-halten-sich-20350390.html
Flash update Wall Street: Inflation data spoils mood - Tech stocks suffer the most - Biogen, Coca-Cola, Tripadvisor and Waste Management in Focus
deraktionaer.de/artikel/maerkte-forex-zinsen/blitz-update-wall-street-inflationsdaten-verderben-stimmung-tech-werte-leiden-am-staerksten-biogen-coca-cola-tripadvisor-und-waste-management-im-fokus--20350384.html
(BIIB) Biogen Sales Miss Estimates as Multiple Sclerosis Drugs Decline: Biogen Inc. reported fourth-quarter revenue that missed Wall Street expectations as the ...
bloomberg.com/news/articles/2024-02-13/biogen-sales-miss-estimates-as-multiple-sclerosis-drugs-decline
An overview of selected quarterly figures in the coming week from February 12th. until February 16th 💡
Biogen to shut down controversial Alzheimer's drug Aduhelm: Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential ...
apnews.com/article/biogen-alzheimer-aduhelm-dfb364a61e4e77da27fc055e826b9a49
Quick Glance: Biogen Halts Production of Alzheimer’s Drug Aduhelm
- Biogen halts production of Alzheimer’s drug Aduhelm, focusing on Leqembi and developing other treatments for the disease.
- The decision to end development of the drug was not related to safety or efficacy concerns.
- The US Food and Drug Administration will end its study needed for full approval of the drug.
- The US Congress criticized the collaboration between Biogen and the FDA, concluding that the high price of the drug was unjustified.
Biogen Ends Development of Alzheimer’s Drug Aduhelm: Biogen will record a one-time charge of about $60 million related to close-out costs of the program.
barrons.com/articles/biogen-alzheimers-drug-aduhelm-ends-development-a6e0c402
Paid articlePaid China approves Alzheimer's treatment Leqembi by Eisai and Biogen: Eisai (4523.T) and Biogen (BIIB.O) said on Tuesday that their Alzheimer's treatment Leqembi had ...
reuters.com/business/healthcare-pharmaceuticals/china-approves-alzheimers-treatment-leqembi-by-eisai-biogen-2024-01-09/
Quick Glance: VW utilizing ChatGPT for driver conversations by mid-year
- Volkswagen integrating ChatGPT to enable driver conversations by mid-year.
- First vehicles with ChatGPT available in North America and Europe from early second quarter.
- AI system capable of recognizing and responding to various demands, such as temperature adjustments and displaying nearby restaurants.
China approves Alzheimer's treatment Leqembi by Eisai and Biogen: Eisai (4523.T) and Biogen (BIIB.O) said on Tuesday that their Alzheimer's treatment Leqembi had ...
reuters.com/business/healthcare-pharmaceuticals/china-approves-alzheimers-treatment-leqembi-by-eisai-biogen-2024-01-09/
Controversial Alzheimer's drug exits the stage: Its fast-track approval in 2021 sparked urgent conversations about how the health care system could afford new ...
axios.com/2024/02/01/aduhelm-azlheimers-biogen-ends
More potential than AI values? According to experts, this industry could surprise everyone in 2024
boerse-online.de/nachrichten/aktien/mehr-potenzial-als-ki-werte-diese-branche-koennte-laut-experten-2024-alle-ueberraschen-20347686.html
New Alzheimer's drug to be covered by health insurance in Japan: The drug, to be launched Dec. 20, will cost around ¥2.98 million per year in Japan but patients ...
japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/
Biogen cuts profit forecast on higher deal costs: (This Nov. 8 story has been corrected to say Biogen cut profit forecast due to costs related to a deal ...
reuters.com/business/healthcare-pharmaceuticals/biogen-cuts-annual-profit-forecast-persistent-higher-costs-2023-11-08/
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900: Sage Therapeutics (SAGE.O) has priced the oral postpartum depression (PPD) pill it ...
reuters.com/business/healthcare-pharmaceuticals/biogen-sage-therapeutics-postpartum-depression-pill-priced-15900-2023-11-07/
The War In Alzheimer's Treatment Is Just Beginning: Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
investors.com/news/technology/biotech-stocks-the-war-in-alzheimers-treatment-is-just-beginning-why-there-is-still-hope/
Eisai-Biogen Alzheimer's therapy to cost ¥2.98 mil per year: A single course of treatment with an Alzheimer's drug developed by Japanese company Eisai ...
japantoday.com/category/features/health/update1-eisai-biogen-alzheimer&
$BIIB - Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript). seekingalpha.com/article/4654622-biogen-inc-biib-evercore-isi-6th-annual-healthconx-conference-transcript?source=feed_f&utm_campaign=twitter_automated&utm_content=article&utm_medium=social&utm_source=twitter_automated #business #stocks #economy
Earnings playbook: How to trade the biggest reports this week, including Disney: More than 45 S&P 500 names are slated to report this week, including Disney ...
cnbc.com/2023/11/05/earnings-playbook-how-to-trade-the-biggest-reports-this-week-including-disney.html
Paid articlePaid Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi: An injected version of Eisai (4523.T) and Biogen's (BIIB.O) Alzheimer's drug ...
reuters.com/business/healthcare-pharmaceuticals/injected-version-eisaibiogen-alzheimers-drug-effective-side-effects-higher-2023-10-25/
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug: Swiss pharmaceutical company Roche (ROG.S) has settled a patent lawsuit against U ...
reuters.com/business/healthcare-pharmaceuticals/roche-settles-us-patent-lawsuit-against-biogen-over-blockbuster-arthritis-drug-2023-10-23/
Biogen Experimental Alzheimer’s Drug Shows ‘Favorable Trends’ (BIIB): Biogen Inc. said it saw “favorable trends” in patients taking its experimental Alzheimer’s ...
bloomberg.com/news/articles/2023-10-25/biogen-s-experimental-alzheimer-s-drug-shows-favorable-trends
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen: Japan's Eisai (4523.T) said on Monday its Alzheimer's treatment developed with Biogen (BIIB.O) ...
reuters.com/business/healthcare-pharmaceuticals/japan-approves-alzheimer-treatment-leqembi-by-eisai-biogen-2023-09-25/
Biogen, Sage face challenges as FDA rejects pill for clinical depression: The approval of Biogen (BIIB.O) and Sage Therapeutics' (SAGE.O) depression pill for a ...
reuters.com/business/healthcare-pharmaceuticals/biogen-sage-face-uphill-battle-with-postpartum-depression-pill-2023-08-07/
Quick Glance: FDA approves first medication for postpartum depression
- The FDA has approved the first medication specifically for treating severe depression after childbirth.
- The drug Zurzuvae by Sage Therapeutics has been approved for adults with severe depression related to childbirth or pregnancy.
- Postpartum depression affects an estimated 400,000 people per year and can last for weeks, months, or even years.
- Zurzuvae was studied in two company trials and showed a reduction in depression symptoms over a period of four to six weeks.
Major US health systems expect to offer Alzheimer's drug Leqembi in a few months: Five major U.S. health systems said they would offer Eisai and Biogen's ...
reuters.com/business/healthcare-pharmaceuticals/major-us-health-systems-expect-offer-alzheimers-drug-leqembi-few-months-2023-08-07/
Quick Glance: Major US health systems to offer Alzheimer's drug Leqembi in a few months
- Five major US health systems will offer the promising new Alzheimer's drug Leqembi.
- The drug is expected to be rolled out in the next few months.
- Neurologists at renowned clinics like Mayo Clinic, Northwestern Memorial, and Cedars-Sinai also plan to introduce the drug.
- Medicare is expected to reimburse the drug.
ChrysCapital-backed Intas Pharma weighs $1-bn bid for Biogen's biosimilars biz
vccircle.com/chryscapitalbacked-intas-pharma-weighs-1-bn-bid-for-biogen-s-biosimilars-biz
Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce
investors.com/news/technology/biogen-stock-biogen-announces-7-3-billion-acquisition-of-reata-pharmaceuticals/
Quick Glance: Biogen acquires Reata for $6.5 billion to strengthen rare disease portfolio
- Biogen agrees to acquire biotech firm Reata Pharmaceuticals for nearly $6.5 billion to strengthen its position in the market for rare disease drugs.
- Through the agreement, Biogen will gain Reata's recently approved drug Skyclarys, which treats a rare genetic disorder causing progressive damage to the nervous system.
- Biogen is seeking deals to expand beyond its multiple sclerosis drugs portfolio, particularly in the areas of rare diseases and immunology.
- The acquisition of Reata aligns with Biogen's objective of near-term sales growth.
Sage Therapeutics to lay off about 40 percent of its workforce: The job cuts come after the FDA gave only limited approval to the Cambridge company’s new ...
bostonglobe.com/2023/08/31/business/sage-therapeutics-lay-off-about-40-percent-its-workforce/
Biogen announces job cuts, turns focus to Alzheimer's drug launch: Biogen Inc (BIIB.O) said on Tuesday it expects to slash about 1,000 jobs ...
reuters.com/business/healthcare-pharmaceuticals/biogen-cut-1000-jobs-save-costs-alzheimers-drug-launch-gathers-pace-2023-07-25/
Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug
cnbc.com/2023/08/07/sage-therapeutics-plunges-after-fda-decision-on-depression-drug.html
Biogen, Sage Pill Is First Cleared for Postpartum Depression: A fast-acting depression pill from Biogen Inc. and Sage Therapeutics Inc., the first specifically ...
bloomberg.com/news/articles/2023-08-04/biogen-sage-pill-is-first-cleared-for-postpartum-depression
Roche sues Biogen over biosimilar of blockbuster arthritis drug: Roche (ROG.S) and two of its subsidiaries sued biotech company Biogen (BIIB ...
reuters.com/legal/litigation/roche-sues-biogen-over-biosimilar-blockbuster-arthritis-drug-2023-07-14/
Quick Glance: Roche Sues Biogen Over Biosimilar of Blockbuster Arthritis Drug
- Roche's billion-dollar drug treats both COVID-19 and rheumatoid arthritis.
- Roche claims Biogen's similar version would infringe patents.
Japanese panel OKs Alzheimer's drug by Eisai and Biogen: TOKYO (Kyodo) -- A Japanese health ministry panel on Monday gave the green light for the manufacture and ...
asia.nikkei.com/Business/Pharmaceuticals/Japanese-panel-OKs-Alzheimer-s-drug-by-Eisai-and-Biogen
Paid articlePaid Biogen Makes Biggest M&A Bet to Date on Rare Diseases with Reata Deal: Hi, it’s Michelle Davis in New York. Today, we’re putting the spotlight on a biotech deal ...
bloomberg.com/news/newsletters/2023-07-28/biogen-makes-biggest-m-a-bet-to-date-on-rare-diseases-with-reata-deal
Lilly Joins Biogen as Alzheimer’s Drugs Finally Emerge : In trials, Biogen and Eli Lilly have shown that their drugs can slow early-stage decline in the disease ...
barrons.com/articles/lilly-joins-biogen-as-alzheimers-drugs-finally-emerge-c5a3235f
Paid articlePaid
Biotech: Biogen employees in Baar are worried about their job: The drug manufacturer Biogen is cutting more than every ninth job worldwide ...
nzz.ch/wirtschaft/biotech-angestellte-von-biogen-in-baar-zittern-um-den-job-ld.1752534
US FDA grants standard approval of Eisai/Biogen Alzheimer's drug: Eisai (4523.T) and Biogen's (BIIB.O) Leqembi won a coveted standard approval nod from the U.S ...
reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-standard-approval-eisaibiogen-alzheimers-drug-2023-07-06/
Quick Glance: FDA Expands Access to Alzheimer's Drug Leqembi
- Medicare will cover most of the high cost.
- Alzheimer's experts say the evidence supporting Leqembi is much clearer.
- The decision to grant full approval to Leqembi means that Medicare will cover it for eligible patients.
- However, some patients may be unable to afford the 20 percent that Medicare does not cover, amounting to about $6,600 per year.
Biogen outperforms Sanofi - by 50 cents: large pharmaceutical and biotech companies are looking for interesting acquisition targets.
deraktionaer.de/artikel/pharma-biotech/biogen-sticht-sanofi-aus-um-50-cent-20337735.html
Alzheimer's Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off. : Two similar Alzheimer’s drugs are likely to be on the market and accessible for ...
barrons.com/articles/alzheimers-drugs-competition-lilly-biogen-4cdc6c6
Paid articlePaid Alzheimer's: Biogen CEO Viehbacher aims to score in second attempt.: Biogen, the biotechnology company, suffered an ignominious defeat in the launch of its first ...
nzz.ch/wirtschaft/nach-dem-flop-mit-dem-alzheimer-medikament-aduhelm-biogen-nimmt-in-der-demenz-behandlung-einen-zweiten-anlauf-ld.1744964
Quick Glance: Alzheimer: Biogen CEO Viehbacher aims for success with Leqembi
- Biogen hopes for a breakthrough with Leqembi in the second attempt
- Christopher Viehbacher sees potential in the new drug
- Viehbacher brings extensive experience in the pharmaceutical industry
- Biogen's previous Alzheimer's drug Aduhelm was not successful
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
cnbc.com/2023/07/17/alzheimers-eli-lilly-expects-fda-decision-on-donanemab-by-year-end.html
The first drug that slows Alzheimer's has finally received FDA approval: Japanese drugmaker Eisai and US-based Biogen have received FDA approval for Leqembi ...
engadget.com/the-first-drug-that-slows-alzheimers-has-finally-received-fda-approval-165058452.html
Eli Lilly's Alzheimer's treatment shows promising results: Patients taking Lilly’s drug in a clinical trial showed a 35 percent slowing of decline compared to ...
bostonglobe.com/2023/07/17/business/eli-lilly-alzheimers/
Markets in the morning: Nemetschek, Stabilus, DHL Group, Covestro, Biogen, Procter & Gamble, T-Mobile US
Meta surges as 100M sign up for its Threads platform. Here's how to play the stock
cnbc.com/2023/07/10/meta-surges-as-100m-sign-up-for-threads-heres-how-to-play-the-stock.html
Paid articlePaid Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes: Activist investor Sarissa Capital may have cleared a stumbling block in its push for board ...
reuters.com/business/healthcare-pharmaceuticals/sarissas-denner-quits-biogen-board-firm-seeks-seats-alkermes-2023-06-13/
European Alzheimer's experts unconvinced by new Eisai, Biogen drug: Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai (4523 ...
reuters.com/business/healthcare-pharmaceuticals/european-alzheimers-experts-unconvinced-by-new-eisai-biogen-drug-2023-06-13/
Biogen shares fall after Alzheimer’s drug approval. Here's what the pros are saying
cnbc.com/2023/07/07/biogen-falls-after-alzheimers-drug-approval-what-the-pros-are-saying.html
Paid articlePaidNew to NewsWall?
Sign up now to get your own personalized news!
Trending topics